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The amino acid sequence of the first of a family of insect cardioregulatory peptides from the tobacco hawkmoth, Manduca sexta, has been 
detern~ined using a combination f Edman degradation mlerosequencmg and mass pectroscopy This peptide contmns 9 amino acid residues and 
an observed mass for the monoL~otop~c protonated mol~ule of 956 4 Da. There are two ¢ystemes at pnstt~ons 3 and 9 forming a disulfide bridge 
and the carboxyl-terminns l~ amldated. The ~tructure ofthis peptide, Pro-Phe-Cy~-Asn-Aia-Phe-Thr-Gly-Cys-Ntt:, is identical to a peptide recently 
i~olated from crab~ called crustacean eard~oact~ve pepttde (CCAP) and we propoh¢ that this pept~de be named Manduca CCAP. 
Cardmr~gulation, l .~ect neuropeptid¢; Invertebrate neuropcptide 
1. INTRODUCTION 
The insect heart is modulated in r ive by several neu- 
rohurnoral factors, including the biogenic amine octo- 
pamine, as well as by a number o f  neurally derived 
peptides [1]. Included in this latter group are the cardio- 
aeceleratory peptides (CAPs), a family of  peptides 
which have been studied extensively in the tobacco 
hawkmoth,  Manduca sexta [2]. Early wolk isolated a 
pair of  CAPs, known as CAP~ and CAP2, from the 
Manduca central nervous ystem [3]. Physiological stud- 
ies have determined that the CAPs act as cardiostimula- 
tory neurohormones twice in adult Manduca, once im- 
mediately alter adult emergence to facilitate wing infla- 
t ion [4,5] and again during flight episodes for increased 
blood circulation between abdomen and thorax [6]. The 
CAPs are also functionally active in earlier developmen- 
tal stages, for which the hindgut is the primary target. 
One of the CAPs, CAP2, is released during the latter 
stages ofembryogenesis to stimulate the initial contrac- 
tions of tlac hindgut [7]. CAP~ is also released in caterpil- 
lars at the beginning of  metamorphosis to trigger clear- 
ing of the alimentary canal [8]. The CAPs thus serve a 
variety of  stage-specific functions throughout his or- 
ganism's life cycle. 
Despite the extensive physiological work on the Man- 
duca CAPs, their primary structures have remained un- 
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resolved, in large part due to the paucity of available 
material to analyze. These difficulties have been com- 
pounded by the recent report that there are at least 2 
distinct CAP~s and 3 CAP:s [9]. This paper reports on 
the elucidation of  the amino acid sequence of the first 
of  the CAP2s using microsequencing techniques. 
2. MATERIALS  AND METHODS 
Tile abdominal portion of the ventral nerve cord (ANC) from over 
6,000 phamte adult moths were dissected and stored at -20°C Frozen 
AblCs were heat-treated at 8O°C for 5 toni and extracted m0.5 M 
at'eric acid Following an initial low pressure ~paration through a 
O18 cartridge ($ep-pak, Waters), CAP bloaetway was purified to 
homogeneity using a 6-step HPLC procedure who~e details are de- 
seabed m Table 1 Tile first lbur HPLC steps were performed by 
rcver~c-phase HPLC using an lseo model 2350 system and standard 
bore (4.6 mm and 2.1 ram) columns [10l. The final two chromato- 
graplnc nteps used mlerobore (i.0 ram and 0.5 mm) columns and a 
syringe pump HPLC. All chromatographic steps u~.~l variations of a 
~tandard acetomtnle gradient in dilute TFA or I'IFBA [10]. Each step 
was spectrophotometrie,dly monitored at 200 (step 6) or 215 nm (~tepb 
t-5) and CAP-eont~inmg l'ractlons confirmed using an lsolatt.~l 
pharate adult heart bioassay [3,5,8] The pept~de p ak from the filth 
purification ~tap was subjected to amino acid ~,.--Xlueneing on an Ap- 
phed Blosystems 670A sequencer qmpped with a lrfH on-line ana- 
lyzer. Following a sixth chromatography step, the same peak v~a~ 
analyzed further on a Finnigan MA'f TbQ-700 tnple sector quadruple 
mass pectrometer using a 10 kV C~ ion primary beam and thioglye- 
erol a~ the sample matrix. 
3. RESULTS 
Isolation and purification of  the CAPs first required 
that the CAP~s were fully separated from the CAP~.s, 
and this was accomplished by the initial HPLC run 
(Table 1). The second chromatography step fraction- 
ated the combined CAP2 activities into three distinct 
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Table I 
Purtllcatten procedure for isolation of Manduca CCAP/CAP..~ 
Step Column Column size Flow rate AGradient A---~B Counter mn 2. (nm) 
1 Sphen-50DS 220 × .5 6 mm 
2 Aquapor¢ 300 220 × 4.6 mm 
3 Aquapore 300 220 x 4 6 mm 
4 Aquapore 300 220 × 2 1 mm 
5 Aqaapore 300 250 × 1 0 mm 
6 Vydac C-18 300 x 0,5 mm 
1 ml min -t 
1 ml ,  rata -L 
1 ml ,  min -~ 
250 gtl, mm-) 
50 pl rain -~ 
20 ~¢1 mm -h 
2% rain -t TFA 215 
0 5% rain -~ HFBA 215 
0,1%, rain -t TF# 215 
0.25% rain -~ TFA 215 
0.1% rain -~ TFA 215 
2% mm -t TFA 200 
Columns used in ~tep~ 1-5 wore manufaetttred by the Brownlee Corporation, All runs were performed at room temperature, TFA. tr~fluoroaee:ie 
acid; HFBA, heptalltlorobutyrlc acid 
bioactive peaks, which we have called CAP.~, CAP2t), 
and CAP:,. This paper focusses exclusively on the anal- 
ysis of CAP2,. Four additional HPLC steps, including 
a final run using a 0.5 mm i.d. microbore column at very 
low flow rates, were required to pmify CAP.~ to homo- 
geneity. Peptide purity was confirmed using Edman 
degradation, which produced a single residue signal in 
each cycle. From an initial starting sample of 6,000 
ANCs we obtained about 150 pmol of pure CAP.~,. 
The Edman degradation results from a starting sam- 
ple of approximately 80 pmol are shown in Table I1. 
With the exception of cycle 3, strong signals were ob- 
tained in each cycle. The low yield in cycle 3 compared 
that from other cycles suggested that the assignment of 
Tyr at residue 3 might be open to other interpretations. 
One likely possibility was that the Tyr signal of cycle 3 
was the result of a partially oxidized Cys residue that 
co-chromatographed with Tyr. This hypothesis was in- 
vestigated by analyzing the s,tme sample with mass 
spectrometry, which yielded a mass of 956.4 for the 
protonated molecule (Fig. 1). This is the value that 
would be calculated if the sequence from the Edman 
degradation was modified to include a Cys at positions 
3 and 9 joined by a disulfide bond and with an amide 
at the C-terminus. MS/MS analysis of the molecular ion 
gave a daughter ion spectrum consistent with this struc- 
ture (data not shown). Fragmentation ions from the 
parent peptide were relatively weak, as would be ex- 
pected for a cyclized molecule. Nonetheless, there was 
sufficient sequence information to confirm the proposed 
structure. 
To test the validity of the MS/MS data, we had the 
proposed sequence synthesized by American Peptide 
Co., Sunnyvale, CA. The synthetic peptide co-eluted 
precisely with native CAPz~ on each of the first 5 HPLC 
purification steps. For technical reasons, the final mi- 
crobore step was not tested. When assayed on an iso- 
lated pharate adult Manduca heart, native and synthetic 
pept;.des produced identical dose-dependent eardioexei- 
tatory responses (Fig. 2). Both synthetic and native pep- 
tides were biologically inactivated upon reduction with 
performic acid (data not shownL Based on these results, 
166 
we conclude that the primary sequence of CAP2, is Pro- 
Phe-Cys-Asn-Ala-Phe-Thr-Gly-Cys-NHa. 
4. DISCUSSION 
The data presented here firmly establishes th~ amino 
acid sequence of one of the CAPs, CAP~, using Edman 
degradation and mass spectrometry procedures. The 
mass of the protonated molecule (m/z 956.4) for this 
nine-residue peptide is in the range of  values determined 
previously by gel filtration on Sephadex G-15 (ca. 500 
Da) [3,4]. This nonapeptide exhibits several distinctive 
properties for a neuropeptide: (i) although water soluble 
it is very hydrophobic, a characteristic which explains 
the long retention times on all reverse-phase colmnns, 
and (ii) it is cyclized, with the two Cys residues forming 
a disulfide bridge in the active conformation. This latter 
conclusion is supported by previous reports which 
showed that CAP~ lost much of its bioactivity when 
exposed to reducing agents such as performic acid 
[10,11]. These studies also demonstrated that the C- 
terminal amide was required for biological activity. 
A search of the protein data base at the National 
Center for Biotechnology Information at the National 
Library of Medicine revealed only one other peptide 
Table II 
Amino aeLd sequence of Manduca CCAP/CAP,, using Edman degra- 
dation 
Residue no, ldentity Ymld (pmol) 
1 Pro 76.8 
2 Pha 78.7 
3 (Tyr) 5.8 
4 Asn 32.6 
5 Ala 25.8 
6 Phe 26.6 
7 Thr 20.9 
8 Gly 13.8 
l 0  - - 
l [  - - 
Cy¢le.~ 9-11 yielded no detectible signal. 
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Fig, 1 Molecahtr ion reg~on of the posattve ton mass spectrum of CAPh/CCAP 
with a significant degree of homology (more than 2 
residues) to CAP.~. This was crustacean cardioactive 
peptide (CCAP), an invertebrate peptide originally iso- 
lated from the perieardial organs of the shore crab, 
Carcinus maenas [12], whose structure is 100% homolo- 
gous, including the C-terminus amlde, with CAP~. 
CCAP appears to be widely distributed among the crus- 
tacea, with CCAP-Iike bioaetivity isolated from other 
crabs, such as the edible crab Cancer pagurus, and the 
crayfish, Orconectes lhnosus [13]. Although its function 
is unknown, CCAP is a potent cardioexcitor in all these 
crustacea, producing both motropic and chronotropie 
effects when applied to semi-isolated hearts [13]. CCAP 
has also been isolated in an insect, Locusta migratoria, 
CAP2, ~ (.~Brv¢ Cord. l;qulval.ent Unit) o 
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Fig. 2. The effects ot'natwe CAP2, and ~yntheuc CCAP on the ~solated 
M,,&ou heart b,oas~ay, Each point r~pre'e~t.. :!' e meaq +_ S E M of 
at least 8 dlfl%rent assayn with the exeepuon of the 5 nerve cord 
eqmvalent CAPz~ data point which is the average of 5 replicate assays, 
(o) Native CAP~,; (m) byatheti¢ CCAP. 
but in that species it is the hindgut rather than the heart 
that is tnost sensitive to CCAP application [14]. Thus, 
there is a striking degree of overlap between CCAP's 
pharmacological profile in crustaceans and locusts, and 
the physiology of the CAPs in Manduca since the CAPs 
have been shown to have physiologically significant ac- 
tions on both the hindgut and heart [2,6]. Because 
CAP~ and CCAP share identical structures and targets, 
we propose that CAP~ be renamed as Manduca CCAP. 
The present elucidation of the primary structure of 
Manduca CCAP should provide a springboard for fu- 
ture molecular studies on its physiology and mode of 
action in regulating insect behavior. 
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